Vanguard Group Inc Esperion Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 11,487,729 shares of ESPR stock, worth $9.76 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,487,729
Previous 11,715,748
1.95%
Holding current value
$9.76 Million
Previous $25.8 Million
35.82%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ESPR
# of Institutions
200Shares Held
119MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$11.9 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$9.29 Million0.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$8.24 Million0.32% of portfolio
-
Two Seas Capital LP Rye, NY6.93MShares$5.89 Million0.36% of portfolio
-
Morgan Stanley New York, NY6.59MShares$5.6 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $56.6M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...